

The societal challenge 'Health, demographic change and well-being' Work Programme 2017

Information Day, Brussels 8 July 2016



Ruxandra Draghia-Akli, MD, PhD
Director
DG Research and Innovation

Research and innovation – a growing priority for the EU Horizon 2020 supports Commission priorities



- Jobs and growth
- Societal challenges
- European industrial leadership and competitiveness
- EU international excellence



- Couple research to innovation
- Provide evidence-base for addressing societal challenges, supporting EU policies and better regulation
- Strengthen research capacities and innovation strategies across all Member States
- Multidisciplinarity and synergies
- Address people's concerns





Ways to measure impact

Evidence based policy making



Medicines for children





and many others...

Taking the lead in new areas of growth



Personalised medicine

Responding to emergencies



conduct research of the Zika virus.

MOSCOW (Sputnik) — The European Commission allocated 10 million euros (\$11.1 million) on Tuesday to support research into the Zika virus, the body said in a statement.

The money, taken from the Horizon 2020 EU research and innovation funding program, will be spent to prove the link between Zika and severe brain defects, including cases of microcephaly, in newborns. Should the link be proven, the rest of the funding will be

Knowledge creation and exploitation









Health Research in H2020





IMI 2: ~ € 3.2 billion EC: € 1.6b + EFPIA €1.4b + other (€0.2b)

IMI2:

- Covers the entire medical research and innovation value chain
- Strategic Research Agenda is based on the WHO Priority Medicine Report renewed in July 2013
- Involves pharmaceutical industries as well as others (diagnostics, imaging, animal health, ICT etc.)
- Supports World class research and innovation leading to breakthrough vaccines, medicines and treatments



European & Developing Countries Clinical Trials Partnership

EDCTP 2: ~ € 1.37 billion EC: € 683 mio + MS €683 mio

EDCTP2:

- launched in December 2014
- almost €700 million EU co-funding, matching the same Member States contribution
- broader scope: including HIV, TB, malaria, neglected infectious diseases, all clinical phases, diagnostics and delivery optimisation
- longer duration: 10 years



SC1 Work Programme 2017 in brief

Call 'Personalised Medicine'
11 topics

Including 'coordination activities' 4 topics

- SME Instrument2 topics (unchanged from 2016)
- Other Actions12 items (incl. InnovFin ID and Birth Day Prize)





Topics amended in SC1 WP 2017 calls

- PM-07 (Promoting Mental Health): Reference to migrants
- PM-20-2017: Development of new methods & measures for improved economic evaluation + efficiency measures in health sector
- SC1-HCO-07-2017: Global Alliance for Chronic Diseases (GACD) – Topic on mental health developed
- NEW HOA: Support to the 'World RePORT', Tracking research outcomes
- Additional budget: 48 M€, +35 M€ to SMEs-5, +13 M€ to PM-02,-08,-10

Final version to be adopted end of July 2016. SUBJECT TO CHANGE!

Topics amended in SC1 WP 2017 calls

- NEW SC1-HCO-17-2017: CSA for Support for large scale uptake of Digital Innovation for Active and Healthy Ageing
- PM-16, 17 and 19 -2017: minor textual changes for further clarification
- PM-15: Personalised coaching for well-being and care of people as they age: budget increased by 1.5 M EUR to 26.5 M EUR

Final version to be adopted end of July 2016. SUBJECT TO CHANGE!



2nd European Summit on Digital Innovation for Active and Healthy Ageing

5-8 December 2016, Brussels





Details will soon be announced at http://ec.europa.eu/eip/ageing



Developing personalised medicine at EU level



- Europe is a leader in personalised medicine
- Personalised medicine drives innovation and contributes to sustainable healthcare by better prevention, prediction and disease management strategies
- Personalised Medicine Conference 2016 has launched IC PerMed



European Human Biomonitoring Initiative

- Launch Event of the European Human Biomonitoring Initiative: 8 December
 2016, Brussels, under the Slovakian Presidency of the Council of the EU
- Creating a European joint programme for monitoring and scientific assessment of human exposures to chemicals and potential health impacts – 26 countries and the European Commission, co-funded by Horizon 2020
- Coordinating HBM initiatives in Europe at national and EU level with special focus on a two way dialogue between policy and science in support of evidence based policy making

 Main aim: to coordinate and advance human biomonitoring in Europe and thereby provide better evidence of the actual exposure of citizens to chemicals to support policy making

Commission

Health Horizon Prizes

Horizon Prize

BETTER USE OF ANTIBIOTICS

Can you crack the challenge?

Scope: discover a rapid test to identify, at the point of care, patients with upper respiratory tract infections that can be treated safely without antibiotics.

Funding: C 1 million

Submit your entry until 17 August

2016

Award ceremony: November 2016

'challenge' prizes
offering a cash
reward to
whoever can most
effectively meet a
defined challenge



Joint initiative between the European Commission and Bill & Melinda Gates Foundation (possible additional fundings with MSD for Mothers)

Funding: € 2 million

Scope: a novel solution to improve the outcome of facility-based deliveries (of a clinical, technological or managerial nature, or a combination of these)

End date: 6 September 2017





Horizon 2020: more opportunities for SMEs



- Integrated approach around 20% of the total budget for societal challenges and LEITs to go to SMEs
- Simplification of particular benefit to SMEs (e.g. single entry point)
- A new SME instrument will be used across all societal challenges as well as for the LEITs
- A dedicated activity for research-intensive SMEs in 'Innovation in SMEs'
- 'Access to risk finance' with a dedicated SME scheme (debt and equity facility)





SME instrument WP 2017

SMEInst-05 Supporting innovative SMEs in the healthcare biotechnology sector (RTD)

- 35 million EUR budget increase for 2017!
- a) 'cell technologies' all remaining cut-off dates in 2016 for phase I and for phase II. All cut-off dates in 2017 for phase II only.
- b) 'validation of biomarkers and/or diagnostic medical devices' - only phase II for the first cut-off date in 2017 only.

SMEInst-06 Accelerating market introduction of ICT solutions for Health, Well-Being and Ageing Well Phase I and phase II for all remaining cut-off dates in 2016 and 2017

Final version of the WP to be adopted Europe 1 1019 2016. SUBJECT TO CHANGE!

end of July 2016. SUBJECT TO CHANGE!

Timetable 2017 Work Programme

Amended work programme 2017:

Adoption and opening of calls planned for **end July 2016**

- 2017 call deadlines: No amendments!
 - ✓ RTD 2-stage: 04 October 2016 (first-stage), 11 April 2017 (second-stage)
 - ✓ RTD single-stage: 11 April 2017
 - ✓ CNECT (PM-15): 31 January 2017
 - ✓ CNECT (PM-16, -17, -19): 14 March 2017
- Outlook to work programme 2018-2020... Adoption planned for 4th quarter 2017

Final version of the WP to be adopted end of July 2016. SUBJECT TO CHANGE!

Participation of UK entities

- Before and during negotiations under Art. 50, the UK remains a full member of the European Union with all the rights and obligations in the Framework Programmes for Research and Innovation that derive from this.
- During this time a UK organisation will be treated like any other organisation from an EU Member State in a call for proposals or call for tender.





Thank you for your attention!